title: Pharmacological treatment and the prospect of pharmacogenetics in Parkinson's disease.
abstract: Parkinson disease (PD) is a progressive movement disorder marked by tremor, rigidity, bradykinesia and postural instability. Levodopa (l-dopa), usually combined with a peripheral dopa decarboxylase inhibitor, has been proved to provide the best symptomatic benefit for PD. However, its long-term efficacy is limited because of motor complications and drug-induced dyskinesia. Dopamine agonists, catechol-O-methyltransferase inhibitors and monoamine oxidase-B inhibitors are anti-parkinsonian (anti-PD) drugs that have been found to further improve the potency of l-dopa and prevent the onset of motor complications. However, as PD is a progressive disorder, all the drugs used for its therapy, manifest reduced efficacy and adverse effects with time. Research on the field of pharmacogenetics has pointed out that the genetic variability of each individual determines to a large extent the inter-individual variability in response to anti-PD drugs. Clinicogenetic trials show that drug efficacy or toxicity or susceptibility to side effects are features governed by genetic principles. This article is a review of the present pharmacological treatment of PD and current pharmacogenetic data for PD.
authors.affiliation: Department of General Biology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
authors.forename: K
authors.initials: K
authors.lastname: Kalinderi
authors.forename: L
authors.initials: L
authors.lastname: Fidani
authors.forename: Z
authors.initials: Z
authors.lastname: Katsarou
authors.forename: S
authors.initials: S
authors.lastname: Bostantjopoulou
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use*; D002394:Catechol O-Methyltransferase / Q000235:genetics; D005544:Forecasting; D006801:Humans; D008995:Monoamine Oxidase / Q000235:genetics; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic / Q000235:genetics; D011954:Receptors, Dopamine / Q000235:genetics
chemical_list: D000978:Antiparkinson Agents; D011954:Receptors, Dopamine; D008995:Monoamine Oxidase; D002394:Catechol O-Methyltransferase